About this episode
A CNBC investigation into counterfeit weight loss drugs revealed an international illegal marketplace where criminals either brazenly alter the drugs or ship the real product from overseas — what’s known as drug diversion and against federal law.
The operations mainly involve phony or illegal versions of Novo Nordisk’s diabetes drug Ozempic and its obesity drug Wegovy as well as Eli Lilly’s Mounjaro and Zepbound. All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. The skyrocketing demand for the treatments has led to criminal schemes attempting to capitalize on the surge.
To view the documentary and read the full article go to https://cnb.cx/3NfQO8V Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com
for information about our collection and use of personal data for
advertising.
Get every episode summarized
Each time CNBC's "Fast Money" publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
